Anna Chen

University of Pennsylvania

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Johns Hopkins Medicine

Research Subjects

Research Interests

Anna Chen has a total of 120 co-authors. Here are the top co-authors by number of shared publications:

Alex Lieberman-Cribbin
Icahn School of Medicine at Mount Sinai, New York, USA
32 shared publications
Alfred L. Garfall
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
32 shared publications
Andrew Jay Portuguese
Fred Hutchinson Cancer Center, Seattle, USA
32 shared publications
Ariel F. Grajales-Cruz
Moffitt Cancer Center, Tampa, Florida, United States
32 shared publications
Danai Dima
Fred Hutchinson Cancer Center, Seattle, WA 98109, USA
32 shared publications
Douglas W. Sborov
Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
32 shared publications

Latest Publications

Sort by

Website
Google Scholar
- 25 September 2026
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
Relative risk and onset of strabismus in children with Chiari malformation
by Anna Chen, Alexander Tucker, Fangming Jin, Yinxi Yu, Gil Binenbaum
Website
Google Scholar
- 25 September 2026
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
Relative risk and onset of strabismus in children with Chiari malformation
by Anna Chen, Alexander Tucker, Fangming Jin, Yinxi Yu, Gil Binenbaum
Website
Google Scholar
- 9 February 2026
- Published by Elsevier in Ophthalmology
Onset of Ocular Abnormalities in Children with Hearing Loss
by Anna Chen, Erin O’NEil, Emily Datz, Yinxi Yu, Gui-Shuang Ying, Katie Choi, Gil Binenbaum
Website
Google Scholar
- 9 February 2026
- Published by Elsevier in Ophthalmology
Onset of Ocular Abnormalities in Children with Hearing Loss
by Anna Chen, Erin O’NEil, Emily Datz, Yinxi Yu, Gui-Shuang Ying, Katie Choi, Gil Binenbaum
Website
Google Scholar
- 1 January 2026
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
When Sarcoidosis Looks Like Myeloma: A Diagnostic Pitfall
by Anna Chen, Keenen D. Smith, Roseann I. Wu, Kevin Ma, Sandra P. Susanibar Adaniya
Website
Google Scholar
- 1 January 2026
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
When Sarcoidosis Looks Like Myeloma: A Diagnostic Pitfall
by Anna Chen, Keenen D. Smith, Roseann I. Wu, Kevin Ma, Sandra P. Susanibar Adaniya
Open Access
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Open Access
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Relationship between PFS and time from last BCMA-directed therapy or serum ferritin
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Relationship between PFS and time from last BCMA-directed therapy or serum ferritin
Open Access
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table 6. Best Overall Response
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S6 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table 6. Best Overall Response
Open Access
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table S8: Multivariable regression for overall response
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S8 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table S8: Multivariable regression for overall response
Open Access
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table 2: Prior BCMA-directed therapy details
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table 2: Prior BCMA-directed therapy details
Open Access
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S11 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table 11. Progression Free Survival Univariable and Multivariable Regression Analyses
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S11 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table 11. Progression Free Survival Univariable and Multivariable Regression Analyses
Open Access
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Table S13 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table S13: Progression-free survival univariable and multivariable regression analyses among patients with ≥VGPR
Website
Google Scholar
- 11 November 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S13 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
by Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, et al.
Supplemental Table S13: Progression-free survival univariable and multivariable regression analyses among patients with ≥VGPR

Show all